@ImmunityBio
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen patients’ natural immune system to fight cancer.
Culver City, CA
Joined March 2020
- Tweets964
- Following131
- Followers20.5K
- Likes611
We've completed the database lock for our QUILT-2.005 trial evaluating ANKTIVA® plus BCG as a potential first locally delivered, chemotherapy-free combination for BCG-naïve bladder cancer.
Topline results are expected in November 2026, with supplemental Biologics License Application submission on track for Q4 2026.
Learn more: immunitybio.com/immunitybio-…
ImmunityBio is excited to attend the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid - a highly influential global oncology meeting bringing together clinicians, researchers, patient advocates, and industry leaders from around the world.
#ESMO26 will be a platform for advances in oncology research, clinical practice, and patient care.
We look forward to engaging with the global oncology community, exploring impactful new data, and contributing to the future of cancer care on a global scale. @myESMO
New Phase 3 data published in the @JUrology highlights long‑term durability findings from our QUILT‑3.032 study evaluating ANKTIVA® plus BCG in patients with BCG‑unresponsive #NMIBC, with 84% cystectomy‑free survival at three years and complete responses extending beyond 53 months.
Read the full press release: immunitybio.com/immunitybio-…
We are pleased to announce that the U.S. Food and Drug Administration (@FDA) has expanded the indication for ANKTIVA® (nogapendekin alfa inbakicept‑pmln) + BCG to include patients with BCG‑unresponsive non‑muscle‑invasive bladder cancer (NMIBC) with papillary‑only tumors.
This milestone makes ANKTIVA + BCG the first FDA‑approved therapy for both CIS and papillary‑only disease in the BCG‑unresponsive NMIBC setting. Because papillary tumors represent approximately 85 % of NMIBC diagnoses, this approval significantly broadens access to a bladder‑sparing option for patients who face high risk of recurrence and progression.
Read more: immunitybio.com/fda-expands-…
ImmunityBio, Inc. retweeted
Big news for bladder cancer patients! FDA just expanded approval of Anktiva with BCG for adults with BCG-unresponsive, high-grade papillary-only NMIBC — the first treatment approved for this group. This is a first, and that matters. Evidence from a closely related form of bladder cancer supported the approval.
fda.gov/drugs/resources-info…
ALT The image announces that the FDA has approved the first treatment for patients with BCG-unresponsive bladder cancer. It features a purple and orange awareness ribbon and the FDA logo.
We're hiring at our new Dunkirk facility.
ImmunityBio is expanding our manufacturing operations and seeking talented professionals in Manufacturing & Operations, QA/QC, Process Engineering, and Regulatory Affairs. Join us in our mission to develop innovative immunotherapies that transform patient outcomes.
Apply now: immunitybio.com/careers/
ImmunityBio, Inc. retweeted
@DrPatrick will join @Piper_Sandler Virtual Oncology Symposium on Oct 16, 1PM ET for a fireside chat on ImmunityBio’s clinical progress and vision for cancer immunotherapy.
immunitybio.com/immunitybio-…
Contact Piper Sandler for information about attending the symposium and accessing session recordings.
According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States.
Through clinical research and collaboration, ImmunityBio is researching medications aiming to help those affected.
Learn more about our research and clinical trials: immunitybio.com/non-small-ce…
ImmunityBio, Inc. retweeted
Strong patient-centered care starts with listening.
Today, patients, caregivers, patient leaders, and urologic experts came together at our first Annual Patient & Caregiver Conference to share perspectives, learn from one another, and explore ways to strengthen the patient voice.
Through meaningful discussions on communication, health literacy, access to care, and collaboration, attendees identified opportunities to improve the experience of patients and families across the urologic community.
Thank you to everyone who participated and contributed to a day of thoughtful conversation, connection, and shared learning.
We're excited to join the World Bladder Cancer Patient Forum 2026 in Hong Kong, bringing together voices from across the globe to advance bladder cancer care and advocacy.
Today, ImmunityBio's Anjali Malhotra joined a panel on patient-centric clinical trial design, contributing to an important conversation about putting patients at the center of research.
#BladderCancerForum26
ImmunityBio, Inc. retweeted
What an honor to meet with President Erdogan today. Under his leadership Turkey will be the center of excellence for patients with cancer in the region.
President @RTErdogan, who is in New York for the 81st session of the United Nations General Assembly, received Dr. Patrick Soon-Shiong at the Turkish House.
On World Lymphoma Awareness Day, we stand with the more than 1 million people worldwide living with lymphoma, including those facing Non-Hodgkin's Lymphoma, the most common form of this disease.
At ImmunityBio, we are dedicated to advancing innovative immunotherapy approaches that are being studied for patients with Non-Hodgkin's Lymphoma.
Today, we honor the patients, caregivers, and healthcare providers confronting lymphoma every day. Your strength drives our science.
ImmunityBio is expanding our team. We're seeking passionate professionals across research, clinical development, manufacturing, and corporate functions who share our commitment to advancing immunotherapy.
Explore open roles: immunitybio.com/careers
September is Ovarian Cancer Awareness Month, a time to shine light on a disease that often goes undetected until its later stages.
At ImmunityBio, researchers continue working to develop new treatment options for women facing ovarian cancer. Our work is driven by a commitment to develop investigational immunotherapies where options are limited.
We honor the strength of patients and families navigating this journey, and we remain dedicated to advancing research that could transform outcomes.
Learn more about our research: immunitybio.com/ovarian-canc…
This past Sunday, we proudly participated in @GO2forLungCancr's first Annual 5K in Nashville. We joined patients, caregivers, and advocates with a shared commitment to improve outcomes for those affected by lung cancer.
Thank you to everyone who helped make this event a success. Every step helped raise awareness, support the lung cancer community, and reinforce our commitment to advancing treatment options for patients.
Together, we're moving the fight against lung cancer forward – one step at a time.
We're excited to welcome Dr. Jim Yong Kim, former President of the World Bank Group and global health leader, to ImmunityBio as Vice Chairman.
Dr. Kim will join our newly formed Office of the Executive Chairman, where he'll focus on strengthening the company’s international and global relationships. His decades of experience at the intersection of medicine, public health, and development will be instrumental as we work to bring the benefits of immune activation to patients worldwide.
Read more: immunitybio.com/immunitybio-…
ImmunityBio reports Q2 2026 net product revenue up 92% to a record $50.7 million, marking the eighth consecutive quarter of sequential revenue growth since the commercial launch of ANKTIVA®, driven by continued adoption among U.S. urologists and strong market access. First-half 2026 net product revenue totaled $94.8 million, up 121% compared with the first half of 2025.
Access the full announcement: immunitybio.com/immunitybio-…
Meaningful conversations about clinical trials and the future of bladder cancer happening at #BCANTT26. ImmunityBio is grateful to stand with @BladderCancerUS in their mission to support patients and caregivers every day. #BladderCancer
ImmunityBio has received marketing authorization in the United Arab Emirates for ANKTIVA® with BCG across two indications: BCG-unresponsive non-muscle invasive bladder cancer with CIS with or without papillary tumors and BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors, and metastatic non-small cell lung cancer. This authorization expands our global regulatory footprint to 34 countries and marks another important step in broadening access to innovative immunotherapy options for patients worldwide.
Learn more: immunitybio.com/immunitybio-…
